ImmunoCellular Therapeutics, Ltd (NYSE: IMUC) announces the presentation today of updated efficacy data from the phase II trial of dendritic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE